Selected article for: "vaccine development and viral vector"

Author: Gurwith, Marc; Condit, Richard C.; Excler, Jean-Louis; Robertson, James S.; Kim, Denny; Fast, Patricia E.; Drew, Stephen; Wood, David; Klug, Bettina; Whelan, Mike; Mallett Moore, Tamala; Khuri-Bulos, Najwa; Smith, Emily R.; Chen, Robert T; Kochhar, Sonali
Title: Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) standardized template for collection of key information for benefit-risk assessment of live-attenuated viral vaccines
  • Cord-id: xupfh6wd
  • Document date: 2020_10_16
  • ID: xupfh6wd
    Snippet: Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would
    Document: Several live-attenuated viral vaccine candidates are among the COVID-19 vaccines in development. The Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) has prepared a standardized template to describe the key considerations for the benefit-risk assessment of live-attenuated viral vaccines. This will help key stakeholders assess potential safety issues and understand the benefit-risk of such vaccines. The standardized and structured assessment provided by the template would also help to contribute to improved communication and support public acceptance of licensed live-attenuated viral vaccines.

    Search related documents:
    Co phrase search for related documents
    • Try single phrases listed below for: 1